Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Debt (2016 - 2025)

Ptc Therapeutics (PTCT) has 12 years of Non-Current Debt data on record, last reported at $286.0 million in Q2 2025.

  • For Q2 2025, Non-Current Debt changed 0.42% year-over-year to $286.0 million; the TTM value through Jun 2025 reached $286.0 million, changed 0.42%, while the annual FY2024 figure was $285.4 million, 0.42% changed from the prior year.
  • Non-Current Debt reached $286.0 million in Q2 2025 per PTCT's latest filing, roughly flat from $285.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $573.2 million in Q3 2023 and bottomed at $281.6 million in Q3 2021.
  • Average Non-Current Debt over 5 years is $364.3 million, with a median of $285.3 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: soared 102.81% in 2022, then tumbled 50.29% in 2023.
  • A 5-year view of Non-Current Debt shows it stood at $281.9 million in 2021, then surged by 102.81% to $571.7 million in 2022, then crashed by 50.29% to $284.2 million in 2023, then grew by 0.42% to $285.4 million in 2024, then rose by 0.21% to $286.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $286.0 million in Q2 2025, $285.7 million in Q1 2025, and $285.4 million in Q4 2024.